Investor Relationships

Headquartered in Burlington, Massachusetts, USA, Bone Biologics became a public company in September 2014 and is focused on bone repair and regeneration applications. The company is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

Value Proposition

Value Proportion

Opportunity

  • Reduced costs
  • Safer treatment – less complications
  • Fewer reoperations

Physicians

  • Improved clinical outcomes will see physicians / health systems drive utilization
  • Established market and reimbursement

Patients

  • Consumers more selective, demand better care
  • Better safety profile
  • Improved fusions and healing

Strategic Investors

Hankey Capital, LLC|www.hankeycapital.com

Hankey Capital, LLC, a member of the Hankey Group of Companies, is a private equity firm based in Los Angeles, California. The Hankey Group of Companies is one of the largest subprime auto finance lending organizations in the United States and provides a broad array of equity and debt capital solutions to emerging growth companies as well as origination and management of a significant auto and real estate asset-based finance portfolio.

Musculoskeletal Transplant Foundation|www.mtfbiologics.org

Bone Biologics has formed a formal strategic alliance with the Musculo-skeletal Transplant Foundation (MTF) on the collaborative development of osteoinductive products that incorporate MTF’s current product line of natural bone graft substitutes with NELL-1. MTF is the world’s largest allograft supplier and has become one of the major investors in Bone Biologics. It is also the country’s largest full service tissue organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. A non-profit organization, MTF is a consortium of academic medical institutions and organ and tissue recovery organizations across the country. Since its inception in 1987, MTF has recovered tissue from more than 90,000 donors and distributed more than 5 million grafts for transplantation. We anticipate that MTF, with its proven ISO 901 manufacturing and packaging of FDA approved osteogenic carriers, will significantly accelerate the clinical development cycle of NELL-1 related products.

Management Team

Jeff Frelick

Chief Executive Officer | President

Jeff Frelick

Jeff Frelick

Chief Executive Officer | President

Jeffrey Frelick assumed the CEO and President role in June 2019. Previously he served as the Chief Operating Officer of Bone Biologics Inc. since August 2015. Frelick brings more than 25 years of med-tech experience to the position. He spent the past 15 years on Wall Street as a sell-side analyst following the med-tech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard. Prior to becoming an equity research analyst, Frelick worked at Boston Biomedical Consultants where he provided strategic planning assistance, market research data and due diligence for diagnostics companies. He previously held sales and sales management positions at Becton Dickinson’s Primary Care Diagnostic Division after gaining technical experience as a laboratory technologist with Clinical Pathology Facility. Frelick earned a B.S. in Biology from the University of Pittsburgh and an M.B.A. from Suffolk University’s Sawyer Business School.


Deina Walsh

Chief Financial Officer

Deina Walsh

Chief Financial Officer

Deina Walsh was appointed CFO of Bone Biologics in October 2014. Walsh is a certified public accountant and owner/founder of DHW CPA, PLLC a Public Companies Accounting Oversight Board (PCAOB) registered firm since 2014. Prior to forming her firm, Walsh spent 13 years at a public accounting firm where she was actively responsible for leading firm audit engagements of publicly held entities in accordance with PCAOB standards and compliance with SEC regulations, including internal control requirements under section 404 of the Sarbanes-Oxley Act. Her experience includes work with start-up companies and well-established operating entities. She has assisted many entities seeking debt and equity capital. Areas of specialty include mergers, acquisitions, reverse mergers, consolidations, complex equity structures, foreign currency translations and revenue recognition complexities. Walsh earned an A.S. in Business Administration from Monroe Community College and a B.S. in Accounting from the State University of New York at Brockport.


Brent Atkinson, Ph.D.

R&D Consultant

BrentAtkinson

Brent Atkinson, Ph.D.

R&D Consultant

Dr. Atkinson has over 25 years of leading product development, clinical, and regulatory experience in the orthopedic industry. He was previously vice-president of R&D at AlloSource and vice-president of product development at BioSET. He also held roles of Director of R&D at Dentsply and product development scientist at Sulzer Biologics. Dr. Atkinson received his Ph.D. in molecular biology from Columbia University.

Board of Directors

Don R. Hankey, Chairman

CEO/Chairman, Hankey Group

Don Hankey

Don R. Hankey, Chairman

CEO/Chairman, Hankey Group

Mr. Hankey holds his BA and post-graduate work from the University of Southern California. At age 27, Mr. Hankey became Vice President of a major investment banking firm, which would later become part of USB Paine Weber. Mr. Hankey acquired Midway Ford in 1972 and founded Hankey Investment Company in 1982. During the 1980s Mr. Hankey’s organization grew its portfolio and established a foothold in the financial services industry. Mr. Hankey has incorporated technology into every aspect of the Hankey Group of companies improving efficiencies and outcomes. Mr. Hankey has been the manager of Hankey Capital, LLC, since its formation in 2002.


Bruce Stroever, Director

Former CEO, Musculoskeletal Transplant Foundation

Bruce Stroever

Bruce Stroever, Director

Former CEO, Musculoskeletal Transplant Foundation

Mr. Stroever has forty years of product development and general management experience in the medical device and orthobiologics fields. Mr. Stroever joined MTF in late 1988 as General Manager and retired in mid-2018 from his position as the President and Chief Executive Officer of MTF. He served as MTF’s President since his appointment in 1992 and as Chief Executive Officer since 1996. Under Mr. Stroever’s leadership, MTF grew to be the largest tissue bank in the world providing over 500,000 grafts per year with revenues over $400 million. From 1971 to 1988, Mr. Stroever held several positions with Ethicon, Inc., a Johnson & Johnson, Inc. subsidiary. Mr. Stroever currently serves on the advisory board for the New Jersey Organ and Tissue Sharing Network. He was elected to the Board of Governors of the American Association of Tissue Banks for a three year term in 1999 and subsequently in 2012. He was a founding member of the Tissue Policy Group subsidiary of the AATB and served as its Chairman for two terms. Mr. Stroever served as the Chairman of the Bone Biologics Board of Directors from 2012 through mid-2018. Mr. Stroever received his B.E. in Mechanical/Chemical Engineering from Stevens Institute of Technology in 1972 and a Masters of Science in Bioengineering from Columbia University in 1977.


Rob Gagnon

Chief Financial Officer Remix Therapeutics

Rob Gagnon

Chief Financial Officer Remix Therapeutics

Mr. Gagnon brings over 20 years of financial and operational experience in the biotechnology and medical device industries.  He previously served as an operating partner at Gurnet Point Capital, CFO for Veratem Oncology as well as Harvard Biosciences. Earlier in his career Mr. Gagnon spent time at Deloitte & Touche and PricewaterhouseCoopers. Mr. Gagnon holds an MBA from MIT Sloan School of Management and a BA in accounting from Bentley College.


Siddhesh Angle, Ph.D.

President and CEO Regenosine

Siddhesh_Angle

Siddhesh Angle, Ph.D.

President and CEO Regenosine

Dr. Angle has 15 years of musculoskeletal research and development experience. Previously he was the R&D Manager for Zimmer Global Biologics. Dr. Angle has worked at several start ups and successfully commercialized orthopedic medical devices and combination therapies. He holds an MS and Ph.D. from University of Illinois at Chicago.

Frequently Asked Questions

When was the company founded?
The Company was founded in 2004 in Los Angeles, CA

How can I obtain copies of Bone Biologic’s financial reports, or request an investor kit or annual report?
Financial reports are available in the “SEC Filings” page of the “Investors” section of the company’s website. An electronic investor kit is available in the “Electronic IR Kit” section.

Where can I find Bone Biologics’ latest investor presentation?
The company’s most recent investor presentation is available on the “Investors” section on the company’s website. It can also be accessed at the “Events” page of the “Investors” section on the company’s website.

Financial Reporting & Stock Information:

When will Bone Biologics next report financial results?
The company expects to report the financial results for the 12 months ended December 31, 2023 by March 30, 2024.

When is Bone Biologics’ fiscal year end?
The fiscal year ends on December 31.

Where is Bone Biologics stock traded?
Bone Biologics stock is traded on Nasdaq under the symbol “BBLG.”

Has Bone Biologics ever had a stock split?
Bone Biologics implemented a 1-for-8 reverse stock split in December 2023.

Does Bone Biologics pay dividends on its common stock?
Bone Biologics has never declared or paid cash dividends. The company intends to retain any future earnings for the operation and expansion of its business and does not anticipate paying any cash dividends in the foreseeable future.

External Advisors and Contact Information:

Who are Bone Biologics’ independent auditors?
Weinberg & Company, P.A.
1925 Century Park East
Los Angeles, California

Who do I contact to request information on my account or change my account information?
Questions regarding stock holdings, certificate replacement/transfer and address changes should be directed to our
Transfer Agent:

Equiniti Trust Company
Kimberly M Schams
(651) 306-4357
[email protected]
1110 Centre Pointe Curve, Suite 101
Mendota Heights MN  55120

Who is Bone Biologics’ outside corporate counsel?
Harter Secrest & Emery LLP
1600 Bausch & Lomb Place
Rochester, NY 14604-2711

Morse Law
480 Totten Pond Rd
Waltham, MA 02451

How do I contact Bone Biologics Investor Relations?
Please call LHA at (212) 838-3777 and ask for Kim Golodetz or email her at [email protected]. Information requests can be made online via the information request form or e-mail.

Where are Bone Biologics headquarters?
Bone Biologics is headquartered in Burlington, Mass.